Comparative Pharmacology
Head-to-head clinical analysis: POMALIDOMIDE versus REVLIMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALIDOMIDE versus REVLIMID.
POMALIDOMIDE vs REVLIMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and bFGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
None Documented
None Documented
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Deslanoside
"Pomalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePomalidomide + Acetyldigitoxin
"Pomalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent